Two different receptor languages
CJC-1295 and ipamorelin are both discussed as growth-hormone secretagogues, but they act through different receptors. CJC-1295 is a GHRH (growth-hormone-releasing hormone) analog that speaks to the GHRH receptor. Ipamorelin is a selective agonist of the ghrelin receptor, GHS-R1a. This page describes research-compound mechanism for educational purposes only and is not medical advice or a usage recommendation.
CJC-1295 as a GHRH analog
CJC-1295 is engineered from the GHRH (1-29) fragment to resist rapid breakdown, and some versions incorporate a Drug Affinity Complex (DAC) intended to bind albumin and extend half-life. Marketplace naming is notoriously inconsistent—“CJC-1295 with DAC” versus “modified GRF 1-29 without DAC”—so mass and sequence confirmation matters more than the label on a research vial.
Ipamorelin as a selective GHS-R agonist
Ipamorelin is a short synthetic peptide frequently described in the secondary literature as a relatively selective ghrelin-receptor agonist, meaning it is often characterized as having less influence on cortisol and prolactin than some earlier GHRPs such as GHRP-6. Selectivity is a comparative, context-dependent description from research discussion, not a guarantee of any particular profile.
Why they are discussed together
Because the two act on different receptors within the same GH axis, online communities pair them as a “complementary” secretagogue narrative—one nudging the GHRH pathway, the other the ghrelin pathway. That pairing is a marketing and forum convention, not a validated protocol. From an educational standpoint it is simply a very common comparison query.
Research design considerations
Any GH-axis experiment must account for the pulsatile nature of GH release, IGF-1 feedback, and confounds like sleep, nutrition, and assay timing. A single time-point measurement can mislead. These are reasons the primary literature—not vendor blogs—should anchor any experimental interpretation of either compound.
Regulatory framing
Both CJC-1295 and ipamorelin are commonly sold as research materials rather than authorized medicines. In Canada, peptides marketed for human use without authorization are treated as unapproved drugs, and “research use only” labeling does not change that classification. Treat these as laboratory reagents in any discussion here; this is not a suggestion to use them.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Teichman et al. (2006) — CJC-1295 in healthy adults
Human pharmacokinetic and GH/IGF-1 study of CJC-1295 with DAC; not evidence for every product sold as CJC-1295.
Relevant sections: Two different receptor languages · CJC-1295 as a GHRH analog · Why they are discussed together
- Raun et al. (1998) — Ipamorelin, a selective growth hormone secretagogue
Original preclinical receptor and hormone-release work; does not validate consumer stacks or human recovery claims.
Relevant sections: Two different receptor languages · Ipamorelin as a selective GHS-R agonist · Why they are discussed together
- Health Canada (2026) — unauthorized injectable peptides bought online
Canadian safety and authorization notice for the products described. It does not establish approval status in every country.
Relevant sections: Regulatory framing
FAQ
What is the main mechanistic difference?+
CJC-1295 is a GHRH-receptor analog; ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a). They act on two different receptors within the growth-hormone axis. This is educational information, not medical advice.
Is ipamorelin "more selective" than older GHRPs?+
It is frequently described that way in secondary literature—characterized as having less effect on cortisol and prolactin than some earlier GHRPs. Selectivity is a comparative research description, not a guarantee, and primary literature should guide any interpretation.
Are these approved for human use?+
They are generally sold as research materials, not authorized medicines. In Canada, peptides marketed for human use without authorization are treated as unapproved drugs, and RUO labeling does not create a legal exemption.